The mesolimbic dopamine system regulates cognitive, motivational and behavioral processes critical to normal functioning. Dysfunction in this system has been linked to psychiatric disorders such as schizophrenia. Our research is focused on trying to better understand the regulation of the dopamine system in both normal and disease states. Using techniques such as, in vivo electrophysiology, molecular biology and behavior we are attempting to develop novel treatments for schizophrenia. This includes pharmacological, neurosurgical and cell based methods. We strongly believe that a better understanding of the pathophysiology associated with neuropsychiatric disease is essential for the development of novel therapeutic approaches.
"Postnatal mechanisms of cognitive development in mice"
Hiroi (PI) - Lodge (Co-I)
NIMH R01 MH099660
2022 - 2027
This grant examines potential whilte matter abnormalities in mice with CNVs associated with psychiatric illness (Tbx1, 16p11.2 deletion and 22q11.2 hemizygous deletion).
"Transcranial direct current stiimulation for the treatment of post-traumatic stress disorder - from rodent models to clinical studies"
Lodge (PI), Carreno (Co-PI), Straud (Co-PI)
CBN Center Grant Pilot - UTHSCSA
01/22 - 12/23
The major goal of this project is to obtain initial preclinical and clinical data examing tDCS as a treatment for PTSD.
"A drug combination to decrase the abuse liability of opioid medications"
President's Translational and Entrepreneurial Research Fund - UTHSCSA
06/2020 - 12/2022
The major goals of this project are to examine a novel drug combination in reacreational drug users.
"Evaluation of novel compounds for the treatment of psychosis"
Contract (Lodge PI)
10/2020 - 11/2023
The major goal of this project is to examine the preclinical utility and mechanisms of action fo novel antipsychotic drugs.
"HAT-TRIC - Hormone ablation therapy: Treatment to restore impaired cognition"
Morilak (PI) - Lodge (MPI of Project 2)
This is a program project grant aimed at better understanding the cognitive side effects of androgen deprivation, used to treat prostate cancer, and the examination of potential novel treatments to restore impaired cognition. Dr. Lodge is an MPI of project 2 entitled “Elucidation of the role of genetic variation on androgen-regulated neuronal behavior and cognition”.
"Aberrant dopamine system function in a rodent model of perimenopause: relevance to psychosis"
The major goal of this project is to examine potential brain mechanisms contributing to the increased risk of psychosis in perimenopausal women.